| abstract |
Compounds of formula (I) are described in which R1 is optionally substituted heteroaryl; R2 is optionally substituted aryl or optionally substituted heteroaryl; R3 is a group -L?1-R7 or -L2-R8¿ [where L1 is an optionally substituted alkylene linkage; R7 is hydrogen, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, nitro, -S(O)¿nR?9, -NHSO¿2R?9, -C(=Z)0R10, -C(=Z)R?10, -N(R11¿)-C(=Z)R?9, -NY1Y2, -SO¿2-NY1Y2,-C(=Z)-NY?1Y2, -N(R11¿)-C(=Z)-NY?1Y2, -N(OR10¿)-C(=Z)-NY?1Y2, -N(OR10¿)-C(=Z)R10, -C(=NOR10)R10, -C(=Z)NR?10OR12, -N(R11)-C(=NR13)-NY1Y2¿ or -N(R11)-C(=Z)OR11; L2 is a direct bond or a straight- or branched-carbon chain comprising from 2 to about 6 carbon atoms and contains a double or triple carbon-carbon bond; and R8 is hydrogen, aryl, cycloalkenyl, cycloalkyl, heteroaryl or heterocycloalky]; R4 is a group -L3-R14 [where L3 is a direct bond or an optionally substituted alkylene linkage and R14 is hydrogen, alkyl, azido, hydroxy, alkoxy, aryl, arylalkyloxy, aryloxy, carboxy (or an acid bioisostere) cycloalkyloxy, heteroaryl, heteroarylalkyloxy, heteroaryloxy, heterocycloalkyl, heterocycloalkyloxy, nitro, -NY?4Y5, -N(R10¿)-C(=Z)-R?15; -N(R10¿)-C(=Z)-L4-R16, -NH-C(=Z)-NH-R15, -NH-C(=Z)-NH-L?4-R16, -N(R10)-SO¿2-R?15, -N(R10)-SO¿2-L4-R16, -S(O)¿nR?9, -C(=Z)-NY4Y5 or -C(=Z)-OR9); R5 is hydrogen, alkyl or hydroxyalkyl; or R?4 and R5¿, when attached to the same carbon atom, may form with the said carbon atom a cycloalkyl, cycloalkenyl or heterocycloalkyl ring or a group C=CH¿2; R?6 is hydrogen or alkyl; and m is zero or an integer 1 or 2; and N-oxides thereof, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (I) and N-oxides thereof, and their prodrugs. The compounds are TNF inhibitors and are useful as pharmaceuticals. |